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Abstract: Seven transmembrane (7TM) G-protein-coupled receptor (GPCR) families are important targets for drug discovery, 
and speciﬁ  c antagonists for GPCR can accelerate research in the ﬁ  eld of medicinal chemistry. The chemokine receptor 
CXCR4 is a GPCR that possesses a unique ligand CXCL12/stromal cell-derived factor-1 (SDF-1). The interaction between 
CXCL12 and CXCR4 is essential for the migration of progenitor cells during embryonic development of the cardiovascu-
lar, hemopoietic and central nervous systems, and also involved in several intractable disease processes, including HIV 
infection, cancer cell metastasis, progression of acute and chronic leukemias, rheumatoid arthritis and pulmonary ﬁ  brosis. 
Thus, CXCR4 may be an important therapeutic target in all of these diseases, and various CXCR4 antagonists have been 
proposed as potential drugs. Fourteen-mer peptides, T140 and its analogs, and downsized cyclic pentapeptides have been 
developed by us as potent CXCR4 antagonists. This article describes the development of a number of speciﬁ  c CXCR4 
antagonists in our laboratory, including downsizing.
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Introduction
As a postgenome project, proteomics has been prosperous in life science, and selective ligands involv-
ing protein networks have been valuable and useful for studies on chemical biology. Seven transmem-
brane G-protein-coupled receptors (7TM-GPCRs) are great targets for drug discovery and chemical 
biology. Thus, development of selective antagonists against each GPCR is extremely desirable (Tama-
mura and Tsutsumi, 2006). Chemokines are a chemotactic cytokine family that induces migration of 
leukocytes. Receptors of chemokines, which transduce signals of the corresponding chemokines, are 
classiﬁ  ed into GPCR families. The relationships between chemokines and their receptors are highly 
interconnected and complicated: in most cases, a single chemokine recognizes a plurality of receptors, 
and one chemokine receptor recognizes several chemokines. Thus, most of chemokines lack receptor 
selectivity. However, the chemokine CXCL12/stromal cell-derived factor-1 (SDF-1) possesses the 
chemokine receptor CXCR4 as its solitary receptor (Tashiro et al. 1993; Nagasawa, Kikutani and Kishi-
moto, 1994; Oberlin et al. 1996; Bleul et al. 1996). The interaction between CXCL12 and CXCR4 plays 
a fundamental role in the migration of progenitor cells during embryonic development of the hemopoi-
etic, intestine vascular, cardiovascular and central nervous systems. Its physiological roles in adults 
remain poorly disclosed. It is also known that the CXCR4-CXCL12 pair is involved in various disease 
processes such as HIV infection (Feng et al. 1996), cancer cell metastasis (Koshiba et al. 2000; Gem-
inder et al. 2001; Müller et al. 2001; Robledo et al. 2001; Sanz-Rodriguez, Hidalgo and Teixido, 2001; 
Scotton et al. 2001; Bertolini et al. 2002; Kijima et al. 2002; Schrader et al. 2002; Scotton et al. 2002; 
Taichman et al. 2002; Burger et al. 2003; Rubin et al. 2003; Tamamura, Hori et al. 2003; Takenaga et al. 
2004; Mori et al. 2004; Piovan et al. 2005; Zannettino et al. 2005), progression of acute and chronic 
leukemias (Tsukada et al. 2002; Juarez et al. 2003; Burger et al. 2005; Spoo et al. 2007) and rheumatoid 
arthritis (Nanki et al. 2000) (Fig. 1).
CXCR4 was initially identiﬁ  ed as a second receptor (co-receptor) of T cell line-tropic (X4-) HIV-1 
entry through its association with the ﬁ  rst receptor, CD4. Macrophage-tropic (R5-) HIV-1 strains, which 
use the chemokine receptor CCR5 as another co-receptor, are major in early stages of HIV infection 2
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(Alkhatib et al. 1996; Choe et al. 1996; Deng et al. 
1996; Doranz et al. 1996; Dragic et al. 1996). 
However, X4 HIV-1 strains become dominant in 
the late stages. Recently, it has also been reported 
that CXCL12 is highly expressed in several inter-
nal organs that are the primary targets of cancer 
cell metastasis, and that CXCR4 is overexpressed 
on the surfaces of several types of cancer cells. 
Thus, it has been shown that the CXCL12-CXCR4 
axis is associated to metastasis of several types of 
cancer including cancer of the pancreas, breast, 
lung, kidney, and prostate and non-Hodgkin’s 
lymphoma, neuroblastoma, melanoma, ovarian 
cancer, multiple myeloma and malignant brain 
tumors. Furthermore, this axis is also correlated to 
the progression of chronic lymphocytic leukemia 
(CLL) and acute lymphoblastic leukemia (ALL), 
and acute myeloid leukemia (AML). In addition, 
rheumatoid arthritis (RA) is caused mainly by 
CD4
+ memory T cell accumulation in the inﬂ  amed 
synovium. It was reported that CXCL12 concentra-
tion is extremely elevated in the synovium of RA 
Figure 1. Various disorders relevant to the CXCL12-CXCR4 axis, such as HIV infection (i), cancer cell metastasis (ii) and rheumatoid 
arthritis (iii).
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patients, and that CXCR4 is highly expressed on 
the surface of memory T cells. Further, CXCL12 
stimulates migration of the memory T cells and 
thereby inhibits T cell apoptosis. This indicates 
that the CXCR4-CXCL12 interaction plays an 
essential role in the accumulation of T cells in the 
RA synovium. Taken together, CXCR4 is an attrac-
tive therapeutic target for these diseases, and our 
recent research concerning the development of 
several CXCR4 antagonists including downsizing 
is discussed in this review article.
Development of CXCR4 Antago-
nists as Selective Inhibitors of X4-
HIV-1 Entry
Self-defense peptides with antibacterial and anti-
viral activities, tachyplesins and polyphemusins, 
have been isolated from the hemocyte debris of the 
Japanese horseshoe crab (Tachypleus tridentatus) 
and the American horseshoe crab (Limulus poly-
phemus), which are 17-mer and 18-mer peptides, 
respectively (Fig. 2) (Nakamura et al. 1988; Miyata 
et al. 1989). Our preliminary structure-activity 
relationship studies of these peptides led to the 
development of T22 ([Tyr
5,12, Lys
7]-polyphemusin 
II) (Masuda et al. 1992; Nakashima et al. 1992) 
and its downsized 14-mer peptide, T140, which 
possess strong anti-HIV activity (Fig. 2) (Tama-
mura et al. 1998). T22 and T140 effectively block 
X4-HIV-1 entry into cells by binding speciﬁ  cally 
to CXCR4, and inhibit Ca
2+ mobilization caused 
by CXCL12 stimulation against CXCR4 (Murakami 
et al. 1997; Xu et al. 1999; Murakami et al. 1999). 
In addition, a T140 analog exhibited a remarkable 
and signiﬁ  cant delaying of the appearance of drug-
resistant strains of HIV in passage experiments 
using cell cultures in vitro (Kanbara et al. 2001), 
and it was presumed that the T140 analogs would 
be useful for its suppressive effect against drug-
resistant strains. Structural analysis revealed that 
T140 forms an antiparallel β-sheet structure sup-
ported by a disulﬁ  de bridge between Cys
4 and 
Cys
13, which is connected by a type II’ β-turn 
(Tamamura, Sugioka et al. 2001). Four amino acid 
residues that were contained in T140, Arg
2, L-3-
(2-naphthyl)alanine (Nal)
3, Tyr
5 and Arg
14, were 
identiﬁ  ed as residues indispensable for signiﬁ  cant 
activity (Tamamura et al. 2000).
However, T140 is proven to be biologically 
unstable, and biodegradable in mouse/feline serum 
or in rat liver homogenate (Tamamura, Omagari 
et al. 2001; Tamamura, Hiramatsu, Kusano et al. 
2003). When indispensable amino acid residues 
(Arg
14 in serum; Arg
2, Nal
3 and Arg
14 in liver 
homogenate) are deleted from the N- and the C-
termini, the efﬁ  cacy of degraded peptides is dra-
matically reduced. Modiﬁ  cation of T140 analogs 
at both termini efﬁ  ciently suppresses the above 
biodegradations and leads to development of novel 
Figure 2. Structures of tachyplesin I, polyphemusin II, its analog T22, its downsized analog T140, its biostable analogs 4F-benzoyl-TN14003 
and 4F-benzoyl-TE14011.4
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and effective compounds that show highly CXCR4-
antagonistic activity as well as increased biological 
stability. Further studies on the N-terminal modi-
ﬁ  cation found an electron-deﬁ  cient aromatic ring 
such as a 4-ﬂ  uorobenzoyl moiety at the N-terminus 
to constitute a novel pharmacophore for strong 
anti-HIV activity. The T140 analogs, which contain 
an N-terminal 4-ﬂ  uorobenzoyl moiety, 4F-benzoyl-
TN14003 and 4F-benzoyl-TE14011, have anti-
HIV activity two orders of magnitude higher than 
that of T140 and enhanced biostability in serum/
liver homogenates (Fig. 2) (Tamamura, Hiramatsu, 
Mizumoto et al. 2003).
Cyclic Peptides with CXCR4 Antag-
onistic Activity Derived from T140
Arg
2, Nal
3, Tyr
5 and Arg
14 of T140, which are 
located in close proximity to each other in space, 
are indispensable to high antagonistic activity 
against CXCR4 as described above. For downsiz-
ing of T140 analogs, a pharmacophore-guided 
approach was performed using cyclic pentapeptide 
libraries, which were composed of two L/D-Arg, 
L/D-Nal and L/D-Tyr in addition to Gly as a spacer. 
This approach led to FC131 [cyclo(-Arg
1-Arg
2-
Nal
3-Gly
4-D-Tyr
5-)], which showed strong 
CXCR4-antagonistic activity comparable to that 
of T140 (Fig. 3) (Fujii et al. 2003). Structural 
analysis of FC131 by NMR and simulated anneal-
ing molecular dynamics revealed the near-
symmetrical pentagonal backbone structure.
A 4-ﬂ  uorophenyl moiety found as a pharma-
cophoric moiety as described in the above section 
was introduced into cyclic pentapeptides. Since 
replacement of the phenol group of D-Tyr
5 by a 
4-ﬂ  uorophenyl group did not cause the mainte-
nance of high potency, the 4-ﬂ  uorophenyl group 
Figure 3. Structures of cyclic pentapetides FC131, FC401 and FC602.5
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was incorporated into position 1. The resulting 
compound, FC401 ([Phe(4-F)
1]-FC131), shows 
significant CXCR4-binding activity (Fig. 3) 
(Tamamura et al. 2005). Next, since a second Arg 
residue is thought to be indispensable for high 
potency and an aromatic residue [L/D-Phe(4-F)] 
has been incorporated into position 1, four analogs 
[L/D-Phe(4-F)
1, L/D-Arg
5]-FC131 were synthe-
sized based on replacement of D-Tyr
5 by L/D-Arg
5. 
Among these analogs, FC602, which is [D-Phe(4-
F)
1, Arg
5]-FC131, shows the most potent activity, 
which is 10-fold greater than that of [D-Tyr
1, Arg
5]-
FC131 (Fig. 3). Thus, FC602 is a novel lead, which 
involves a pharmacophore moiety different from 
the pharmacophore groups of FC131.
A Linear Type of Low Molecular 
Weight CXCR4 Antagonists
Identification of a novel pharmacophore for 
CXCR4 antagonism, such as a 4-ﬂ  uorobenzoyl or 
4-ﬂ  uorophenyl moiety, prompted us to develop a 
linear type of low molecular weight CXCR4 
antagonists. By combining substructure units of 
the T140 pharmacophore and new pharmacophore 
moieties, several compounds were designed and 
synthesized using combinatorial chemistry. As a 
result, several linear compounds were found as 
moderate CXCR4 antagonists, such as compounds 
1–3 shown in Figure 4 (Tamamura, Tsutsumi et al. 
2006). These compounds are relatively weaker than 
a cyclic pentapeptide FC131. Thus, it is thought 
that conformational constriction based on a cyclic 
pentapeptide scaffold is critical for strong 
potency.
Anthracene derivatives possessing two sets of 
zinc(II)-2,2’-dipicolylamine complex were previ-
ously found as useful chemosensors that can selec-
tively bind to phosphorylated peptide surfaces 
(Ojida et al. 2004). Several low molecular weight 
compounds bearing the complex structure were 
identiﬁ  ed as selective CXCR4 antagonists (Tama-
mura, Ojida et al. 2006). Molecular superposition 
of structures of the zinc(II)-2,2’-dipicolylamine 
complex compound 4 and the cyclic pentapeptide 
FC131 was investigated as it provided the best ﬁ  t 
with the maintenance of local energy minimiza-
tions of both of the structures (Fig. 4). The distance 
between two dipicolylamine moieties of compound 
4 is estimated to be nearly equal to that between 
the two Arg side chains of FC131. Thus, the dis-
tance of these functional groups is thought to be 
Figure 4. Structures of a linear type of low molecular weight CXCR4 antagonists.6
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essential for expression of CXCR4 antagonistic 
activity.
Anti-Metastasis Activity of T140 
Analogs Against Breast Cancer, 
Melanoma and Pancreatic Cancer
While CXCR4 and another chemokine receptor, 
CCR7, are highly expressed on the surface of 
human breast cancer cells, CXCL12 and a CCR7 
ligand, CCL21, are highly expressed in lymph 
nodes, bone marrow, lung and liver, which form 
the common metastatic destinations of breast can-
cer. The CXCL12-CXCR4/CCR7-CCL12 axis 
might determine the metastatic destination of 
tumor cells and cause organ-preferential metasta-
sis (Müller et al. 2001). Metastasis of breast cancer 
cells to the lung in mice was inhibited by neutral-
izing CXCR4 with anti-CXCR4 antibodies. We 
evaluated the inhibitory activity of our T140 ana-
logs against the migration of breast cancer cells in 
vitro and metastasis of breast cancer cells in vivo 
(Tamamura, Hori et al. 2003). T140 analogs inhib-
ited in dose-dependent manners the migration of 
a CXCR4-positive human breast carcinoma cell 
line MDA-MB-231 induced by CXCL12. Further-
more, the inhibitory effect of a bio-stable T140 
analog, 4F-benzoyl-TN14003, was confirmed 
using experimental metastasis models of breast 
cancer, in which MDA-MB-231 cells were injected 
intravenously into the tail vein of SCID mice and 
trapped in the lung to which they migrated through 
the heart and the pulmonary artery. 4F-benzoyl-
TN14003 was subcutaneously injected using an 
Alzet osmotic pump (DURECT Corp., Cupertino, 
CA, U.S.A.), and an effective suppression of tumor 
accumulation was then shown on the lung surface 
as a result of MDA-MB-231 metastasis. This sug-
gests that small molecule CXCR4 antagonists, such 
as T140 analogs, can replace anti-CXCR4 antibod-
ies as neutralizers of metastasis of breast cancer.
It was reported that an excessive expression of 
CXCR4 on B16 melanoma cells enhances the 
metastatic accumulation of the cells in mouse lung, 
and that a CXCR4 antagonist T22 blocks pulmo-
nary metastasis in mice injected with CXCR4-
transduced B16 cells (Murakami et al. 2002). We 
found that T140 analogs inhibited pulmonary 
metastasis in mice injected with B16 cells, which 
are not transduced with CXCR4 (Takenaga et al. 
2004). Poly D,L-lactic acid (PLA) microcapsules 
containing a T140 analog, 4F-benzoyl-TE14011, 
was subcutaneously injected in experimental 
metastatic models of CXCR4-positive B16-BL6 
melanoma cells. 4F-benzoyl-TE14011 is released 
in a controlled fashion from the PLA microcapsules 
for a long period in vivo with the maintenance of 
the level of the 4F-benzoyl-TE14011 concentration 
in blood. A single subcutaneous administration of 
4F-benzoyl-TE14011-PLA signiﬁ  cantly decreases 
the number of colonies ascribed to pulmonary 
metastasis of B16-BL6 cells. Thus, a controlled 
release of CXCR4 antagonists might lead to effec-
tive suppression of cancer metastasis.
While CXCL12 mRNA is expressed in pancre-
atic cancer tissues, CXCR4 mRNA is expressed 
both in pancreatic cancer tissues and in pancreatic 
cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, 
HPAC and PANC-1) (Koshiba et al. 2000). 
CXCL12 stimulates induction of both migration 
and invasion of pancreatic cancer cells, AsPC-1, 
PANC-1 and SUIT-2, in dose-dependent manners 
in vitro. Thus, it suggests that the interaction 
between CXCL12 and CXCR4 is relevant to pan-
creatic cancer cell progression and metastasis. 
CXCL12-induced migration and invasion of these 
cells are suppressed by T140 analogs in dose-
dependent manners (Mori et al. 2004). CXCL12 
treatment of PANC-1 cells induces a drastic 
increase in actin polymerization (cytoskeleton), 
which causes the invasion and subsequent metas-
tasis of malignant cells into tissues. T140 analogs 
effectively inhibit this phenomenon.
Furthermore, the CXCL12-CXCR4 axis is rel-
evant to metastasis of SCLC and osteolysis in 
multiple myeloma. Thus, the blockade of this axis 
might be an effective remedy against these diseases 
(Hartmann et al. 2005; Zannettino et al. 2005).
CXCR4 is expressed in malignant cells in at 
least 23 different types of cancer (Balkwill 2004), 
including those discussed above. Antagonists of 
CXCR4 such as the T140 analogs might be useful 
lead compounds for the development of anti-
metastatic agents in several types of cancer.
Effect of T140 Analogs Against ALL 
and CLL
Growth and survival of ALL precursor B (pre-B) 
cells might be caused by mutual contact with bone 
marrow stromal layers through adhesive interac-
tions between leukemia cells expressing CXCR4 
along with integrins and stromal cells expressing 
CXCL12 and integrin ligands. Migration of these 7
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cells into stromal layers is stimulated by CXCL12, 
which is constitutively secreted at high levels by 
marrow stromal cells, since CXCR4 is highly 
expressed in the pre-B cells. T140 suppresses 
CXCL12-induced chemotaxis of the cells and 
attenuates their migration into bone marrow stro-
mal layers. Furthermore, since T140 analogs 
enhance the cytotoxic and anti-proliferative effects 
of other anti-cancer agents such as vincristine and 
dexamethasone, T140 analogs might overcome cell 
adhesion-mediated drug resistance (CAM-DR) in 
ALL chemotherapy (Juarez et al. 2003).
On the other hand, B cell CLL, which is the 
most frequent leukemia in adults in Western coun-
tries, is caused by the accumulation of long-lived, 
monoclonal, malignant B cells in blood, secondary 
lymphoid organs and bone marrow. CLL B cells 
that highly express CXCR4 are activated by 
CXCL12 released from marrow stromal cells or 
nurselike cells. CXCL12-stimulation rescues the 
CLL B cells from apoptosis and contributes to their 
accumulation. Consequently, the CXCL12-CXCR4 
axis should also be a therapeutic target of B cell 
CLL (Burger et al. 2000). Practically, T140 analogs 
inhibit chemotaxis of CLL B cells induced by 
CXCL12, their migration beneath marrow stromal 
cells and actin polymerization in dose-dependent 
manners, in vitro (Burger et al. 2005). Furthermore, 
T140 analogs attenuate the anti-apoptotic effect of 
CXCL12 and prevent stromal cells from protecting 
against spontaneous apoptosis of CLL B cells. Co-
cultivation of CLL B cells with marrow stromal 
cells causes stromal CAM-DR, protecting CLL B 
cells from undergoing ﬂ  udarabine-induced apop-
tosis. Treatment with T140 analogs re-sensitizes 
these B cells towards ﬂ  udarabine-induced apopto-
sis T140 analogs might overcome CAM-DR which 
is a serious problem in the clinical CLL chemo-
therapy.
Anti-RA Activity of T140 Analogs
The development of biological drugs such as mono-
clonal antibodies, which target inﬂ  ammatory cyto-
kines: tumor necrosis factor, TNF-α, interferon, 
IFN-γ, the interleukins, IL-1, IL-6, etc., has brought 
useful results in clinical RA therapy. However, 
complete curative effects have not yet been 
achieved. Thus, other drugs, which are not relevant 
to the functions of these cytokines, are required to 
improve RA chemotherapy. Since the CXCR4-
CXCL12 axis plays a critical role in the accumula-
tion of memory T cells in the RA synovium (Nanki 
et al. 2000), anti-RA activity of 4F-benzoyl-
TN14003 was evaluated. Delayed-type hypersen-
sitivity (DTH) reaction induced by sheep red blood 
cells (SRBC) was performed as an in vivo experi-
mental model of the cellular immune response 
(Tamamura et al. 2004). Subcutaneous injection of 
4F-benzoyl-TN14003 using an Alzet osmotic pump 
signiﬁ  cantly suppressed the footpad swelling (the 
DTH response) in dose-dependent manners. 
Collagen-induced arthritis (CIA) in mice was 
adopted as the other in vivo experimental RA model. 
Several symptoms of arthritis: score increase, body 
weight loss, ankle swelling, limb weight gain, etc. 
were remarkably suppressed. Furthermore, the 
increase in levels of serum anti-bovine CII IgG2a 
antibody was apparently suppressed in mice treated 
with 4F-benzoyl-TN14003 subcutaneously using 
an Alzet osmotic pump after treatment with the 
bovine type II collagen (CII) emulsion booster. 
4F-benzoyl-TN14003 exhibits an inhibitory effect 
towards the humoral immune response to CII. Thus, 
CXCR4 antagonists such as T140 analogs might 
also be useful leads for anti-RA agents.
Other CXCR4 Antagonists
Several low molecular weight CXCR4 antagonists, 
which are not correlated to T140, have been 
reported to date (Mastrolorenzo, Scozzafava and 
Supuran, 2001; Scozzafava, Mastrolorenzo and 
Supuran, 2002). AMD3100 bearing two cyclam 
groups (Genzyme) (Schols et al. 1997), an N-pyr-
idinylmethylene cyclam (monocyclam) AMD3465 
(Genzyme) (De Clercq, 2002), AMD8665 without 
a cyclam group (Genzyme) (Seibert and Sakmar, 
2004), AMD070 (Genzyme) (Vermeire et al. 
2004), ALX40-4C (Ac-[D-Arg]9-NH2; NPS Alle-
lix) (Doranz et al. 1997), CGP64222 (Cabrera et al. 
2002), R3G (Cabrera et al. 2000), NeoR (Daele-
mans et al. 2000), a distamycin analog, NSC651016 
(Howard et al. 1998) and a ﬂ  avonoid compound, 
ampelopsin (Liu et al. 2004), have been identiﬁ  ed 
as CXCR4 antagonists. Conjugates of AMD3100 
and galactosylceramide (GalCer) analog have also 
been found as doubly-functionalized drugs (Daoudi 
et al. 2004). KRH-1636 (Kureha Chemical and 
Sankyo) is an orally bioavailable agent possessing 
N-pyridinylmethylene, Arg and naphthalene moi-
eties (Ichiyama et al. 2003). A review of non-T140-
related CXCR4 antagonists has been published 
elsewhere (Tamamura and Fujii, 2005).8
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Conclusion
We have found strong anti-HIV agents, T22 and 
its downsized analog T140, identiﬁ  ed as entry 
inhibitors that bind speciﬁ  cally to the chemokine 
receptor CXCR4 and thus inhibit entry of X4-HIV-
1 to T-cells. T140 and its analogs also show effec-
tive activity against cancer metastasis, leukemia 
and rheumatoid arthritis. Cyclic pentapeptide 
FC131 was developed as a new low molecular 
weight CXCR4 antagonist by downsizing of T140. 
Furthermore, a linear type of low molecular weight 
CXCR4 antagonists involving aromatic com-
pounds having the zinc(II)-2,2’-dipicolylamine 
complex structure have been found. These antago-
nists might be promising agents for clinical che-
motherapy of multiple disorders such as HIV 
infection, cancer metastasis, leukemia and RA. 
However, blocking of the CXCL12-CXCR4 axis 
might be a risky procedure because CXCR4 plays 
a critical role in embryogenesis, homeostasis and 
inﬂ  ammation in the fetus especially in the embry-
onic development of hemopoietic, cardiovascular 
and central nervous systems. Use of CXCR4 
antagonists combined with CCR5 antagonists/
fusion inhibitors might lead to a useful candidate 
for clinical AIDS chemotherapy.
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